

Remarks

Applicants hereby state that the changes made in the sequence listing do not include new matter. Applicants have amended the specification only to direct the entry of this corrected Sequence Listing at the end of the application.

In compliance with the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants have amended the sequence listing to provide clear identifiers for multiply defined peptide positions. Also, in accordance with 37 C.F.R. § 1.821(c), Applicants have amended the sequence listing to include 000 at SEQ ID NO:1197 to correct for the missing sequence. Therefore, the tables which list the HBV peptides do not need to be amended.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: June 25, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600